First Time Loading...

RaQualia Pharma Inc
TSE:4579

Watchlist Manager
RaQualia Pharma Inc Logo
RaQualia Pharma Inc
TSE:4579
Watchlist
Price: 601 JPY -1.31%
Updated: May 8, 2024
Section:
 

Wall Street
Price Targets

Price Targets Summary
RaQualia Pharma Inc

Wall Street analysts forecast RaQualia Pharma Inc stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for RaQualia Pharma Inc is 1 836 JPY with a low forecast of 1 818 JPY and a high forecast of 1 890 JPY.

Lowest Forecast
Wall Street Target
1 818 JPY
202% Upside
Average Forecast
Wall Street Target
1 836 JPY
205% Upside
Highest Forecast
Wall Street Target
1 890 JPY
214% Upside
Lowest
Price Target
1 818 JPY
202% Upside
Average
Price Target
1 836 JPY
205% Upside
Highest
Price Target
1 890 JPY
214% Upside
RaQualia Pharma Inc Competitors:
Price Targets
G
002275
Guilin Sanjin Pharmaceutical Co Ltd
7% Upside
C
600062
China Resources Double-Crane Pharmaceutical Co Ltd
15% Upside
Z
300702
Zhejiang Tianyu Pharmaceutical Co Ltd
15% Upside
H
3692
Hansoh Pharmaceutical Group Company Ltd
3% Upside
G
002275
Guilin Sanjin Pharmaceutical Co Ltd
7% Upside
C
600062
China Resources Double-Crane Pharmaceutical Co Ltd
15% Upside
Z
300702
Zhejiang Tianyu Pharmaceutical Co Ltd
15% Upside
H
3692
Hansoh Pharmaceutical Group Company Ltd
3% Upside
AMIORG
Ami Organics Ltd
24% Upside
C
CURA
Curaleaf Holdings Inc
29% Upside
H
2552
Hua Medicine
126% Upside
H
293480
Hana Pharm Co Ltd
50% Upside

Revenue
Forecast

Revenue Estimate
RaQualia Pharma Inc

For the last 8 years the compound annual growth rate for RaQualia Pharma Inc's revenue is 38%. The projected CAGR for the next 1 year is 103%.

38%
Past Growth
103%
Estimated Growth
Estimates Accuracy
-9%
Average Miss
What are analyst estimates?

Operating Income
Forecast

Operating Income Estimate
RaQualia Pharma Inc

Operating Income forecast
is not available for
RaQualia Pharma Inc

Net Income
Forecast

Net Income Estimate
RaQualia Pharma Inc

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
65%
Average Beat
What are analyst estimates?

See Also

Summary
Intrinsic value, competitors valuation, and company profile.
DCF Valuation
Stock valuation using Discount Cash Flow valuation method.
Relative Valuation
Stock valuation using valuation multiples.
Wall Street Estimates
Price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
Stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is RaQualia Pharma Inc's stock price target?
Price Target
1 836 JPY

According to Wall Street analysts, the average 1-year price target for RaQualia Pharma Inc is 1 836 JPY with a low forecast of 1 818 JPY and a high forecast of 1 890 JPY.

What is RaQualia Pharma Inc's Revenue forecast?
Projected CAGR
103%

For the last 8 years the compound annual growth rate for RaQualia Pharma Inc's revenue is 38%. The projected CAGR for the next 1 year is 103%.

ALPHA SPREAD
Join more than 135,300+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2024 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.